134234-12-1 Usage
Description
(1S,2S)-1-(4-HYDROXYPHENYL)-2-(4-HYDROXY-4-PHENYLPIPERIDINO)-1-PROPANOL, also known as Traxoprodil or CP-101,606, is a substituted 4-phenylpiperidine compound with a unique stereochemistry. It is primarily localized in the forebrain neurons and has been identified for its potent and selective antagonistic activity against N-methyl-D-aspartate (NMDA) receptors.
Uses
Used in Pharmaceutical Industry:
Traxoprodil (CP-101,606) is used as a potent and selective NMDA receptor antagonist for the protection of hippocampal neurons, with an IC50 of 10 nM. Its antagonistic properties make it a valuable compound in the development of treatments for various neurological disorders.
Used in Neurological Research:
In the field of neuroscience, CP-101,606 has been utilized to study the role of NMDA receptors in the recovery of spinal cord injuries. Understanding the interaction between Traxoprodil and NMDA receptors can provide insights into potential therapeutic approaches for spinal cord injury patients.
Brand Name:
Traxoprodil is known by its International Nonproprietary Name (INN) as CP-101,606.
Biochem/physiol Actions
Traxoprodil (CP-101,606) is a potent noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors, selective for the NR2B subunit. It has been shown to be neuroprotective in animal models of brain injury and stroke.
Check Digit Verification of cas no
The CAS Registry Mumber 134234-12-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,4,2,3 and 4 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 134234-12:
(8*1)+(7*3)+(6*4)+(5*2)+(4*3)+(3*4)+(2*1)+(1*2)=91
91 % 10 = 1
So 134234-12-1 is a valid CAS Registry Number.
InChI:InChI=1/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3/t15-,19+/m0/s1
134234-12-1Relevant articles and documents
Method for preventing dyskinesias
-
, (2008/06/13)
Dyskinesias in humans are prevented by administering a therapeutically effective dose of a NR1A/2B site-selective NMDA receptor antagonist compound to a human.
Prophylactic use of N-methyl-D-aspartate (NMDA) antagonists
-
, (2008/06/13)
This invention provides a method of inhibiting in a mammal neurological damage resulting from impairment of glucose and/or oxygen supply to the brain, which method comprises administering to the mammal prior to the impairment of glucose and/or oxygen supp
Method for treating diseased-related or drug-induced dyskinesias
-
, (2008/06/13)
Dyskinesias in humans are treated by administering a therapeutically effective dose of an NR1A/2B site-selective NMDA receptor antagonist compound to a human suffering therefrom.
